Enhancing oral delivery of plant-derived vesicles for colitis

Yuan Liu; Adrian Lankenau Ahumada; Emine Bayraktar; Paul Schwartz; Mamur Chowdhury; Sixiang Shi; Manu M. Sebastian; Htet Khant; Natalia de Val; Nazende Nur Bayram; Guodong Zhang; Thanh Chung Vu; Zuliang Jie; Nicholas B. Jennings; Cristian Rodriguez-Aguayo; Jody Swain; Elaine Stur; Lingegowda S. Mangala; Yutuan Wu; Supriya Nagaraju; Brooke Ermias; Chun Li; Gabriel Lopez-Berestein; Janet Braam; Anil K. Sood

doi:10.1016/j.jconrel.2023.03.056

Enhancing oral delivery of plant-derived vesicles for colitis

Yuan Liu, Adrian Lankenau Ahumada, Emine Bayraktar, Paul Schwartz, Mamur Chowdhury, Sixiang Shi, Manu M. Sebastian, Htet Khant, Natalia de Val, Nazende Nur Bayram, Guodong Zhang, Thanh Chung Vu, Zuliang Jie, Nicholas B. Jennings, Cristian Rodriguez-Aguayo, Jody Swain, Elaine Stur, Lingegowda S. Mangala, Yutuan Wu, Supriya NagarajuBrooke Ermias, Chun Li, Gabriel Lopez-Berestein, Janet Braam, Anil K. Sood

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Plant-derived vesicles (PDVs) are attractive for therapeutic applications, including as potential nanocarriers. However, a concern with oral delivery of PDVs is whether they would remain intact in the gastrointestinal tract. We found that 82% of cabbage PDVs were destroyed under conditions mimicking the upper digestive tract. To overcome this limitation, we developed a delivery method whereby lyophilized Eudragit S100–coated cabbage PDVs were packaged into a capsule (Cap-cPDVs). Lyophilization and suspension of PDVs did not have an appreciable impact on PDV structure, number, or therapeutic effect. Additionally, packaging the lyophilized Eudragit S100-coated PDVs into capsules allowed them to pass through the upper gastrointestinal tract for delivery into the colon better than did suspension of PDVs in phosphate-buffered saline. Cap-cPDVs showed robust therapeutic effect in a dextran sulfate sodium-induced colitis mouse model. These findings could have broad implications for the use of PDVs as orally delivered nanocarriers of natural therapeutic plant compounds or other therapeutics.

Original language	English (US)
Pages (from-to)	472-483
Number of pages	12
Journal	Journal of Controlled Release
Volume	357
DOIs	https://doi.org/10.1016/j.jconrel.2023.03.056
State	Published - May 2023

Keywords

Eudragit S100 coat
Gastrointestinal tract
Lyophilization
Oral delivery
Plant-derived vesicles
Vesicle stability

ASJC Scopus subject areas

Pharmaceutical Science

MD Anderson CCSG core facilities

Research Animal Support Facility

Access to Document

10.1016/j.jconrel.2023.03.056

Cite this

Liu, Y., Ahumada, A. L., Bayraktar, E., Schwartz, P., Chowdhury, M., Shi, S., Sebastian, M. M., Khant, H., de Val, N., Bayram, N. N., Zhang, G., Vu, T. C., Jie, Z., Jennings, N. B., Rodriguez-Aguayo, C., Swain, J., Stur, E., Mangala, L. S., Wu, Y., ... Sood, A. K. (2023). Enhancing oral delivery of plant-derived vesicles for colitis. Journal of Controlled Release, 357, 472-483. https://doi.org/10.1016/j.jconrel.2023.03.056

Liu, Y, Ahumada, AL, Bayraktar, E, Schwartz, P, Chowdhury, M, Shi, S, Sebastian, MM, Khant, H, de Val, N, Bayram, NN, Zhang, G, Vu, TC, Jie, Z, Jennings, NB, Rodriguez-Aguayo, C , Swain, J, Stur, E, Mangala, LS, Wu, Y, Nagaraju, S, Ermias, B, Li, C , Lopez-Berestein, G, Braam, J & Sood, AK 2023, 'Enhancing oral delivery of plant-derived vesicles for colitis', Journal of Controlled Release, vol. 357, pp. 472-483. https://doi.org/10.1016/j.jconrel.2023.03.056

@article{ca9973bb0a524424942afb00d327050f,

title = "Enhancing oral delivery of plant-derived vesicles for colitis",

abstract = "Plant-derived vesicles (PDVs) are attractive for therapeutic applications, including as potential nanocarriers. However, a concern with oral delivery of PDVs is whether they would remain intact in the gastrointestinal tract. We found that 82% of cabbage PDVs were destroyed under conditions mimicking the upper digestive tract. To overcome this limitation, we developed a delivery method whereby lyophilized Eudragit S100–coated cabbage PDVs were packaged into a capsule (Cap-cPDVs). Lyophilization and suspension of PDVs did not have an appreciable impact on PDV structure, number, or therapeutic effect. Additionally, packaging the lyophilized Eudragit S100-coated PDVs into capsules allowed them to pass through the upper gastrointestinal tract for delivery into the colon better than did suspension of PDVs in phosphate-buffered saline. Cap-cPDVs showed robust therapeutic effect in a dextran sulfate sodium-induced colitis mouse model. These findings could have broad implications for the use of PDVs as orally delivered nanocarriers of natural therapeutic plant compounds or other therapeutics.",

keywords = "Eudragit S100 coat, Gastrointestinal tract, Lyophilization, Oral delivery, Plant-derived vesicles, Vesicle stability",

author = "Yuan Liu and Ahumada, {Adrian Lankenau} and Emine Bayraktar and Paul Schwartz and Mamur Chowdhury and Sixiang Shi and Sebastian, {Manu M.} and Htet Khant and {de Val}, Natalia and Bayram, {Nazende Nur} and Guodong Zhang and Vu, {Thanh Chung} and Zuliang Jie and Jennings, {Nicholas B.} and Cristian Rodriguez-Aguayo and Jody Swain and Elaine Stur and Mangala, {Lingegowda S.} and Yutuan Wu and Supriya Nagaraju and Brooke Ermias and Chun Li and Gabriel Lopez-Berestein and Janet Braam and Sood, {Anil K.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = may,

doi = "10.1016/j.jconrel.2023.03.056",

language = "English (US)",

volume = "357",

pages = "472--483",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier",

}

TY - JOUR

T1 - Enhancing oral delivery of plant-derived vesicles for colitis

AU - Liu, Yuan

AU - Ahumada, Adrian Lankenau

AU - Bayraktar, Emine

AU - Schwartz, Paul

AU - Chowdhury, Mamur

AU - Shi, Sixiang

AU - Sebastian, Manu M.

AU - Khant, Htet

AU - de Val, Natalia

AU - Bayram, Nazende Nur

AU - Zhang, Guodong

AU - Vu, Thanh Chung

AU - Jie, Zuliang

AU - Jennings, Nicholas B.

AU - Rodriguez-Aguayo, Cristian

AU - Swain, Jody

AU - Stur, Elaine

AU - Mangala, Lingegowda S.

AU - Wu, Yutuan

AU - Nagaraju, Supriya

AU - Ermias, Brooke

AU - Li, Chun

AU - Lopez-Berestein, Gabriel

AU - Braam, Janet

AU - Sood, Anil K.

PY - 2023/5

Y1 - 2023/5

N2 - Plant-derived vesicles (PDVs) are attractive for therapeutic applications, including as potential nanocarriers. However, a concern with oral delivery of PDVs is whether they would remain intact in the gastrointestinal tract. We found that 82% of cabbage PDVs were destroyed under conditions mimicking the upper digestive tract. To overcome this limitation, we developed a delivery method whereby lyophilized Eudragit S100–coated cabbage PDVs were packaged into a capsule (Cap-cPDVs). Lyophilization and suspension of PDVs did not have an appreciable impact on PDV structure, number, or therapeutic effect. Additionally, packaging the lyophilized Eudragit S100-coated PDVs into capsules allowed them to pass through the upper gastrointestinal tract for delivery into the colon better than did suspension of PDVs in phosphate-buffered saline. Cap-cPDVs showed robust therapeutic effect in a dextran sulfate sodium-induced colitis mouse model. These findings could have broad implications for the use of PDVs as orally delivered nanocarriers of natural therapeutic plant compounds or other therapeutics.

AB - Plant-derived vesicles (PDVs) are attractive for therapeutic applications, including as potential nanocarriers. However, a concern with oral delivery of PDVs is whether they would remain intact in the gastrointestinal tract. We found that 82% of cabbage PDVs were destroyed under conditions mimicking the upper digestive tract. To overcome this limitation, we developed a delivery method whereby lyophilized Eudragit S100–coated cabbage PDVs were packaged into a capsule (Cap-cPDVs). Lyophilization and suspension of PDVs did not have an appreciable impact on PDV structure, number, or therapeutic effect. Additionally, packaging the lyophilized Eudragit S100-coated PDVs into capsules allowed them to pass through the upper gastrointestinal tract for delivery into the colon better than did suspension of PDVs in phosphate-buffered saline. Cap-cPDVs showed robust therapeutic effect in a dextran sulfate sodium-induced colitis mouse model. These findings could have broad implications for the use of PDVs as orally delivered nanocarriers of natural therapeutic plant compounds or other therapeutics.

KW - Eudragit S100 coat

KW - Gastrointestinal tract

KW - Lyophilization

KW - Oral delivery

KW - Plant-derived vesicles

KW - Vesicle stability

UR - http://www.scopus.com/inward/record.url?scp=85152636452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152636452&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2023.03.056

DO - 10.1016/j.jconrel.2023.03.056

M3 - Article

C2 - 37031740

AN - SCOPUS:85152636452

SN - 0168-3659

VL - 357

SP - 472

EP - 483

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Enhancing oral delivery of plant-derived vesicles for colitis

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this